CN1180318A - Systems and methods for on-line finishing of cellular blood products like platelets harvested for therapeutic purposes - Google Patents
Systems and methods for on-line finishing of cellular blood products like platelets harvested for therapeutic purposes Download PDFInfo
- Publication number
- CN1180318A CN1180318A CN 97190084 CN97190084A CN1180318A CN 1180318 A CN1180318 A CN 1180318A CN 97190084 CN97190084 CN 97190084 CN 97190084 A CN97190084 A CN 97190084A CN 1180318 A CN1180318 A CN 1180318A
- Authority
- CN
- China
- Prior art keywords
- blood
- container
- platelet suspension
- crude product
- links
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- External Artificial Organs (AREA)
Abstract
Blood processing systems and methods establish on-line communication between a container and a source of blood containing leukocytes and platelets, such as a human donor. The systems and methods create a centrifugal field between the source of blood and the container that separates from the blood an unfinished suspension of platelets having a first physiologic characteristic different than the desired physiologic characteristic. The systems and methods pump the unfinished platelet suspension outside the centrifugal field through a finishing device. The finishing device changes the first physiologic characteristic to the desired physiological characteristic, thereby creating the finished platelet suspension. The system and methods convey the finished platelet suspension from the finishing device directly into the container. The systems and methods function without interrupting the on-line communication between the container and the source of blood.
Description
Invention scope
Generally speaking the present invention relates to blood system of processing and method, more professional theory the present invention relates to from gathering and makes to remove the medical blood constituent leukocytic system and method.
Background of invention
The equipment of the collection blood of today becomes separation of whole blood various therapeutic component routinely, as erythrocyte, and platelet and blood plasma.
A kind of nowadays widely used isolation technics is multiple blood bag system.This blood bag system comprises an elementary blood bag and one or more transfer blood bag that is connected as a single entity by pipe and elementary blood bag.This technology is put into elementary blood bag from the whole blood that the blood donor collects a unit (about 450ml), and the blood donor can freely leave away then.
Next in elementary blood bag with blood donor's whole blood centrifugalize protoerythrocyte be rich in hematoblastic blood plasma.To be rich in hematoblastic blood plasma is transported to the transfer blood bag from elementary blood bag, stay erythrocyte, to be rich in hematoblastic blood plasma then in shifting the blood bag further is centrifugated into spissated platelet and does not contain hematoblastic blood plasma substantially, to not contain hematoblastic blood plasma more substantially and be transported in another transfer blood bag, stay spissated platelet.
Three kinds of main components utilizing multiple blood bag system can collect whole blood are done medical.Yet the output of the various compositions of collection is subjected to the restriction of various component contents in the per unit whole blood.Further, because erythrocyte has been left, U.S. government's regulation has only the whole blood that could gather another unit after six weeks from same blood donor.
Some treatment needs a large amount of single blood constituent of planting of input, and for example, the patient who always treats need import a large amount of platelet on conventional basis, and multiple blood bag system is not a kind ofly to gather a large amount of hematoblastic effective ways from single blood donor.
Nowadays adopt one continuous line (on line) blood separation system to collect a large amount of platelet and be used to satisfy this generic request.The one continuous line system implements essential separating step in the presence of the blood donor, from whole blood, isolate spissated platelet with successive process, the one continuous line system has set up the whole blood that comes from the blood donor and has circulated, from blood flow, isolate required platelet, remaining erythrocyte and blood plasma are returned to the blood donor, and all carry out in a successive blood flow ring.
Adopt streamlined system can process a large amount of whole blood (for example 2.0 liters).Therefore because the botal blood volume of processing is big, can obtain the Platelet Concentrate (for example 4 * 10 of high yield
11Platelet suspension in 200ml liquid).Moreover, since blood donor's erythrocyte has been given back, therefore adopt the blood donor of streamlined system of processing can contribute their whole blood more frequently than the blood donor who adopts multiple blood bag system.
No matter adopt which kind of isolation technics, when blood constituent that collection is used to transfuse blood, must try one's best remove impurity or other can cause the material of unnecessary side reaction in donee's body.For example, because the reaction of possible calentura.Usually the patient's input that needs particularly to need often blood transfusion for patient does not contain leukocytic erythrocyte and platelet substantially.
United States Patent (USP) relates in multiple blood bag system leukocyte be removed from erythrocyte and platelet composition somewhat.For example, U.S. Patent number 4,767,541; 5,089,146; 5,100,564; With 5,128,048.
U.S. Patent number 5,427,695 relate to remove leucocyte-removing from be rich in hematoblastic blood plasma in the streamlined blood course of processing.
That adopts that aforesaid streamlined blood collecting system and method obtain is rich in hematoblastic suspension goods and still may lacks the desired physiological feature that is suitable for long term store and blood transfusion of end user's (generally being blood bank and hospital).For example, be rich in hematoblastic suspension and may contain remaining leukocyte,, but still be higher than the desired leucocyte content standard of end user though compare very faintly with the leukocyte amount in the whole blood.
Therefore, although obtaining remarkable progress aspect the blood process technology, but still need further improve in the mode that is suitable under a large amount of streamlined blood collection environment, operating and from blood constituent, remove unwanted material such as leukocytic system and method.
Summary of the invention
The invention provides the streamlined blood system of processing and the method that are used to prepare platelet suspension finished product with desired physiological property.In a kind of embodiment preferred, desired physiological property comprises a residual white amount that reduces on request.
The system and method that embodies feature of the present invention container and contain leukocyte and hematoblastic blood source such as blood donor between set up streamlined contact.This system and method has been set up a centrifugal district between blood source and container.Centrifugal district isolates from blood has initial physiological feature but not the platelet suspension crude product of desired physiological feature.In a kind of embodiment preferred, this platelet suspension crude product has the initial white cell content and is higher than desired passenger leucocytes amount.
According to the present invention, this system and method pumps centrifugal district by a refining plant with the platelet suspension crude product, this refining plant changes into desired physiological feature with initial physiological feature, obtain the platelet suspension finished product, in an embodiment preferred, this refining plant reduces leucocyte content by filtering.This system and method directly is transported to the platelet suspension finished product from refining plant and is used for the container storing or blood transfusion.
The system and method that embodies feature of the present invention does not interrupt contacting directly between container and blood source when functionating.
Other character of the present invention and advantage can illustrate with claim in find.
Illustrate
Fig. 1 is a blood system of processing diagram, comprises that one embodies the refining plant of feature of the present invention; With
Fig. 2 is the diagram of a centrifugal blood system of processing, and it is the application relevant with refining plant shown in Figure 1.
Under the principle that does not deviate from its spirit or fundamental characteristics, the present invention can be embodied with several forms.Be carried out qualification in scope of the present invention the specifying in additional claim but not in front, allly all will be included in this claim with implication claim and scope equivalent embodiments.The description of embodiment preferred
Fig. 1 is the diagram of the streamlined blood system of processing 10 of embodiment feature of the present invention.According to the present invention, this one continuous line system 10 provides the high-quality hematoblastic blood products finished product (PLT that is rich in
FIN), have leukocyte residual quantity and/or other the enhanced physiological property that obviously reduces, be suitable for long term store and blood transfusion.
The term that present disclosure adopted " streamlined blood separation process " relates to a blood separation system or method, it is 1 years old) between blood source (being generally the blood donor) and external stream, set up contact, 2) drawing a blood volume from the blood donor enters the stream, 3) keep in touch a period of time at least with blood donor's blood circulation, blood sample is separated in external stream therebetween.
" streamlined blood separation process " in the present disclosure can be separated blood sample by continuously or intermittently.Yet should " streamlined blood separation process " keep getting in touch a period of time at least between stream and blood donor, separation process is taken place in stream, and no matter the concrete time limit of separation process itself and order.
" streamlined blood separation process " in this description comprises valve or clip an outside or inner, is used for cutting off that stream flows to the blood donor or from the effusive blood flow of blood donor.Yet in this manual, these valves or clip are not ended the contact between blood donor and stream.On the contrary, when the contact that keeps the two, valve or clip are being controlled flowing of liquid in the stream.
One continuous line system 10 draws whole blood (WB) by a venotomy blood-letting tubulose stream 12 from the blood donor.The main component that WB comprises has erythrocyte, platelet, and leukocyte and blood plasma, system 10 adds anti-agglomerating agent in the whole blood of drawing, then the whole blood of anti-agglomeration is transported to centrifugal district 14 and handles.
In centrifugal district, system 10 whole blood of anti-agglomeration the most at last is divided into two kinds of compositions.First kind of composition is spissated erythrocyte, requires these spissated erythrocyte can carry great majority and is present in leukocyte (LK) among the WB.Thus, first kind of composition is called as RBC
LK+
In the course of processing, RBC
LK+Got back to the blood donor again, this has been avoided the loss of erythrocyte and the quantity of leucocyte of blood donor when obtaining the platelet of high yield.
Second kind of composition is one to be rich in hematoblastic blood plasma suspension crude product PLT
UNWhy claim PLT
UNBe " crude product ", be that the centrifugal treating of carrying out in zone 14 usually can not provide these essential characteristics because this is rich in hematoblastic blood plasma suspension and still lacks the desired physiological property that is suitable for long term store and blood transfusion of end user (normally blood bank and hospital).
Comprise PLT
UNThe concrete physics that is rich in hematoblastic suspension constitute and can change.This formation depends on the effectiveness of centrifugal separation processes greatly.Promptly be to have how many platelet to be separated (platelet yield), what have do not contain hematoblastic blood plasma product substantially be removed and do not return the blood donor.
PLT in this description
UNComprise the suspension of any platelets contained concentration greater than PC in the whole blood.PLT
UNCan comprise that those are commonly referred to is rich in hematoblastic blood plasma (PRP) or platelet concentrate (PC), or between the platelet of the two and the suspension of blood plasma.
Remove outside the platelet PLT
UNThe composition or the composition that also can comprise other according to end user's requirement, for example, PLT
UNCan include only blood plasma as platelet suspension substrate.In addition, except blood plasma, PLT
UNCan comprise that a kind of platelet storage medium of formulism especially is used to the platelet that suspends.
The CONSTRUCTED SPECIFICATION in centrifugal district 14 can change, this is not main for the present invention, for example, zone 14 can be made of a centrifuge, also can be made of the centrifugal Processing Room of multistage, this kind form is seen Brown U.S.5,427,695 or Brown U.S.5,370,802, all be incorporated herein by reference.
Shown in the diagram of Fig. 2, Brown ' 695 or ' 802 described multistage Processing Rooms are separated into RBC and PRP with WB in first separation chamber 16.Occur in as Brown ' 802 or ' special liquid flow kinetics in first separation chamber shown in 695 makes most of leukocyte remove from PRP, the RBC in first separation chamber is then as RBC
LK+Equally get back among the blood donor and go.Occur in Brown ' 802 or ' special liquid flow kinetics in 695 first separation chamber also can provide the platelet that is present in the high yield among the PRP.
Brown ' 802 or ' 695 in, PRP transports from first separation chamber 16, a part is recycled among the WB that flows into first separation chamber 16, and remaining is transported in second separation chamber 18, and PRP is separated into PC and does not contain hematoblastic blood plasma (PPP) substantially in the separation 18 of second Room.
To be trapped among the PPP that PC in second separation chamber 18 is suspended in 1 volume again subsequently or platelet storage medium that (selectable) is fit in, make it as PLT
UNEqually from second separation chamber, transport.Part PPP gets back to the blood donor, and another part PPP stays as recirculation or continues operation or backwash or resuspending medium, or classification is stored or blood transfusion.
Under the said system situation, why claim PLT
UNBeing " crude product ", is because also there is residual leukocyte in platelet suspension, and the passenger leucocytes that these and platelet coexist though its amount is little, but still is higher than the desired leucocyte content standard of end user.
Usually, independent centrifugal treating can not effectively be isolated enough leukocyte to satisfy user's requirement from PRP.Disturbance unintentionally and secondary flowing along the interface (leukocyte is arranged in herein) between RBC and blood plasma may be poured blood plasma from RBC with leukocyte still less.Flow pattern of other desirable heavy leukocyte kind refunds RBC that will be at the interface can not develop its potential the most completely, is complicated with leukocyte and the isolating dynamic process of platelet in the centrifugal process, produces different variations at different blood donors.
Can provide extra step to strengthen initial centrifugal separation processes, be stored in PLT with minimizing
UNIn the passenger leucocytes amount.For example, see Brown ' 695, after coming out from first separation chamber 16, can provide a leucocyte filter 20 that leukocyte is filtered out from PRP, and then enter in second separation chamber 18 and be separated into PC and PPP.Preferably filter 20 is placed in 14 outsides, centrifugal district, links to each other, certainly, also filter 20 can be placed in the centrifugal district 14 with the center of rotation arrangement of a conventional configurations.
In addition, also can link to each other PLT in centrifugal district 14 with other auxiliary leukopenia device
UNBe subjected to the effect of granular layer separation effect, from platelet, isolate leukocyte.Adopt even in centrifugal separation processes these auxiliary device also may not reach the leukopenia degree of customer requirements again.
Therefore (see figure 1), system 10 comprise one be positioned at centrifugal district 14 outer with its refining plant that directly links to each other 24.This pump 26 is with PLT under pressure
UNPump from centrifugal district 14, pass refining plant 24 again.Shown in Figure 1, pump 26 is positioned at 14 downstreams, centrifugal district.Again, pump 26 also can be positioned at the upstream in centrifugal district 14, to provide essential with PLT
UNPressure from 14 outputs of centrifugal district.
Refining plant 24 can be shouldered the desired PLT of influence
UNComposition or the variation of physiology aspect, and can not effectively reach in centrifugal district 14.For example, further reduce leukocytic amount.The refining plant 24 that should directly link to each other is exercised its function on one continuous line, the blood donor still links to each other with system 10 therebetween.
Output is to be rich in hematoblastic suspension finished product (PLT from refining plant 24
FIN).Claim PLT
FINFor " finished product " is because this is rich in the physiological property that is suitable for long term store and blood transfusion that hematoblastic blood plasma suspension has customer requirements.In described concrete scheme, be rich in hematoblastic suspension and comprise PLT
UNHave leucocyte content still less and/or increased some PLT
FINIn non-existent physiological property.
Used in this manual term " minimizing " or " still less " are not meant that all passenger leucocyteses all have been removed.This term only thinks to point out more expressly that behind refining plant 24, residual leukocyte amount is than before having significantly reduced.
Refining plant 24 can be by centrifugal, and post (Columns) is crossed in absorption, chemistry, electronics exercise its function with electromagnetic method.In described embodiment preferred, refining plant 24 comprises that one uses the filter of non-woven fiber filter media 28.
The composition of filter medium 28 can change, and medium 28 is fibrous by tool non-ionic hydrophilic group and nitrogenous alkaline functional group.Such fiber has explanation in United States Patent (USP)s such as Nishimura 4,936,998, this document is also incorporated this paper into as a reference.The filter medium Asahi pharmaceuticals that contains this kind fiber is on sale.Proved that the filter medium that contains this kind fiber can remove the leukocytic hematoblastic loss that reduces simultaneously.In addition, filter medium 28 also can be made of surface treated fiber, and the purpose of processing is when removing leucocyte-removing, and the power that sees through of platelet increasing is seen United States Patent (USP)s 5,258,127 such as Gsell.This patent also is collected herein by reference.
Because pump 26 is to be used for making PLT
UNPass refining plant 24, thus the exterior mechanical pressure that its produces can be used for overcoming refining medium 28 by dynamic resistance.Therefore, can be seated in thick and fast in the refining plant 24 making with extra care medium 28, to reach the highest efficient.
System 10 is with PLT
FINBe transported to one or more be suitable for transfusing blood or the container 30 of long term store in, be used to store PLT
FINContainer 30 constitute (seeing Gajewski etc., United States Patent (USP) 4,140,162) by the polyene material, or by being constituted by the plastifying pvc material of benzenetricarboxylic acid three (2-ethylhexyl) ester (TEHEM).With compare by the plastifying pvc material of DEHP, these materials have better breathability, and are favourable to the preserved blood platelet.
System 10 shown in Figure 1 can easily join in successive single needle or the crosspointer one continuous line blood system of processing and go.
" the streamlined blood separation method " that adopted in this explanation is different from multiple blood bag method.In multiple blood bag method, blood donor's blood circulation does not link to each other with stream always, and the blood sample of collecting in stream is separated.In this system, after blood sample was collected in the primary bag, before separation process took place, blood donor's blood circulation was just separated with primary bag.Again, in multiple blood bag system, separation process can not be carried out continuously.The separation of phase I with erythrocyte be rich in hematoblastic blood plasma and separate, the separation of second stage separates platelet and blood plasma, the separation in two stages occurs in the different time, is discontinuous step independently.
In claims subsequently, listed various feature of the present invention.
Claims (9)
1. be used to obtain have the streamlined blood system of processing of the platelet suspension finished product of desired physiological property, comprise,
One container and contain leukocyte and hematoblastic blood source between set up the tubing that one continuous line is got in touch,
One links to each other with tubing but does not end the device that the one continuous line between container and blood source is got in touch, and this device has a centrifugal district, can from blood, separate to obtain having initial physiological property but not the platelet suspension crude product of desired physiological property,
One be positioned at centrifugal district outside the refining plant that links to each other of tubing, this device contacts with the platelet suspension crude product, and initial physiological property is transformed into desired physiological property, obtains the platelet suspension finished product,
One links to each other with tubing but does not end the pump that the one continuous line between container and blood source is got in touch, and this pump pumps centrifugal district with the platelet suspension crude product, pass again refining plant and
One links to each other with tubing but does not end the pipe that the one continuous line between container and blood source is got in touch, and this pipe directly is transported to the platelet suspension finished product the container from refining plant.
2. be used to obtain to have the streamlined blood system of processing of platelet suspension finished product of the passenger leucocytes amount of minimizing, comprise
One container and contain leukocyte and hematoblastic blood source between set up the tubing that one continuous line is got in touch,
One links to each other with tubing but does not end the device that the one continuous line between container and blood source is got in touch, and this device has a centrifugal district, can separate the platelet suspension crude product of the passenger leucocytes amount that obtains having the initial white cell concentration but not reduce from blood,
One links to each other with tubing, is positioned at the refining plant outside the centrifugal district, and this device contacts with the platelet suspension crude product, and the initial white cell content of crude product is reduced to the passenger leucocytes amount of minimizing, obtains the platelet suspension finished product,
One links to each other with tubing but does not end the pump that the one continuous line between container and blood source is got in touch, and this pump pumps centrifugal district with the platelet suspension crude product, pass again refining plant and
One links to each other with tubing but does not end the pipe that the one continuous line between container and blood source is got in touch, and this pipe directly is transported to the platelet suspension finished product the container from refining plant.
3. according to the system of right 1 or 2, refining element wherein comprises a filter medium.
4. be used to obtain to have the streamlined blood system of processing of platelet suspension finished product of the passenger leucocytes amount of minimizing, comprise,
One container and contain leukocyte and hematoblastic blood source between set up the stream that one continuous line is got in touch,
The segregation apparatus that stream between container with the blood that provides in blood source and acceptance directly links to each other, this segregation apparatus comprises a centrifugalize element, this element is under the situation that the one continuous line of not ending between container and blood source is got in touch, set up a centrifugal district, the platelet suspension crude product that can from blood, separate the passenger leucocytes content that obtains having higher initial white cell content but not reduce
One be positioned at centrifugal district outside the refining plant that directly links to each other of stream, this device have an inlet that links to each other with segregation apparatus with one with container but not the outlet that segregation apparatus links to each other, this device has a refining element, flow to from inlet from export effusive process at the platelet suspension crude product, initial white cell concentration in the platelet suspension crude product is reduced to the passenger leucocytes amount of minimizing
One directly links to each other with stream but does not end the pump that the one continuous line between stream and blood source is got in touch, this pump pumps centrifugal district with the platelet suspension crude product, inlet from refining plant pumps into again, pass refining element, change the platelet suspension crude product into finished product at there, pump from the outlet of refining plant then, enter container.
5. be used to obtain to have the streamlined blood system of processing of platelet suspension finished product of the passenger leucocytes amount of minimizing, comprise,
A stream of between container and whole blood donor, setting up the one continuous line contact,
The separator that stream between container with the whole blood that provides in blood donor and acceptance directly links to each other; This separator comprises a centrifugation element; This element is in the situation that the one continuous line of not ending between container and blood donor contacts; Set up a centrifugal district; Can from whole blood, separate and obtain by first kind of composition of red blood cell and Leucocyles and the second composition that is consisted of by the platelet suspension crude product; This platelet suspension crude product has higher initial white cell content but not the passenger leucocytes content of minimizing
A backflow branch road that directly links to each other with stream when resolution element separates whole blood, is that part is transported the blood donor back with first kind of composition at least,
One be positioned at centrifugal district outside the refining plant that directly links to each other of stream, this device have an inlet that links to each other with segregation apparatus with one with container but not the outlet that segregation apparatus links to each other, this device has a refining element, flow to from inlet from export effusive process at the platelet suspension crude product, initial white cell concentration in the platelet suspension crude product is reduced to the passenger leucocytes amount of minimizing
One directly links to each other with stream but does not end the pump that the one continuous line between stream and blood source is got in touch, this pump pumps centrifugal district with the platelet suspension crude product, inlet from refining plant pumps into again, pass refining element, change the platelet suspension crude product into finished product at there, pump from the outlet of refining plant then, enter container.
6. be used to obtain have the streamlined blood system of processing of the platelet suspension finished product of desired physiological property, comprise,
One at container with contain between the hematoblastic blood source stream of setting up the one continuous line contact,
The segregation apparatus that stream between container with the blood that provides in blood source and acceptance directly links to each other, this segregation apparatus comprises a centrifugalize element, this element is under the situation that the one continuous line of not ending between container and blood source is got in touch, set up a centrifugal district, can from blood, separate and obtain having initial physiological property but not the platelet suspension crude product of desired physiological property
One be positioned at centrifugal district outside the refining plant that directly links to each other of stream, this device have an inlet that links to each other with segregation apparatus with one with container but not the outlet that segregation apparatus links to each other, this device has a refining element, flow to from inlet from export effusive process at the platelet suspension crude product, change its initial physiological property into desired physiological property
One directly links to each other with stream but does not end the pump that the one continuous line between stream and blood source is got in touch, this pump pumps centrifugal district with the platelet suspension crude product, inlet from refining plant pumps into again, pass refining element, change the platelet suspension crude product into finished product at there, pump from the outlet of refining plant then, enter container.
7. according to the system of right 4 or 5 or 6, refining element wherein has a filter medium.
8. an acquisition has the streamlined blood processing method of platelet suspension finished product of the passenger leucocytes amount of minimizing, comprises the following steps
(1) container and contain leukocyte and hematoblastic blood source between set up the one continuous line contact,
(2) between blood source and container, set up a centrifugal district, can from blood, isolate the platelet suspension crude product of the passenger leucocytes amount that has higher initial white cell concentration but not reduce,
(3) make the platelet suspension crude product pass the refining plant that is positioned at outside the centrifugal district with pump, make initial white cell concentration in the platelet suspension crude product be reduced to the passenger leucocytes amount of minimizing, obtain the platelet suspension finished product,
(4) the platelet suspension finished product directly is transported to the container from refining plant,
(5) when carrying out step (2) to (4), the one continuous line of not ending between container and blood source is got in touch.
9. an acquisition has the streamlined blood processing method of the platelet suspension finished product of desired physiological property, comprises the following steps
(1) container and contain leukocyte and hematoblastic blood source between set up the one continuous line contact,
(2) between blood source and container, set up a centrifugal district, can from blood, isolate and have initial physiological property but not the platelet suspension crude product of desired physiological property,
(3) make the platelet suspension crude product pass the refining plant that is positioned at outside the centrifugal district with pump, initial physiological property be transformed into desired physiological property, obtain the platelet suspension finished product,
(4) the platelet suspension finished product directly is transported to the container from refining plant,
(5) when carrying out step (2) to (4), the one continuous line of not ending between container and blood source is got in touch.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 97190084 CN1180318A (en) | 1996-02-23 | 1997-02-10 | Systems and methods for on-line finishing of cellular blood products like platelets harvested for therapeutic purposes |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/606,189 | 1996-02-23 | ||
| CN 97190084 CN1180318A (en) | 1996-02-23 | 1997-02-10 | Systems and methods for on-line finishing of cellular blood products like platelets harvested for therapeutic purposes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1180318A true CN1180318A (en) | 1998-04-29 |
Family
ID=5178625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 97190084 Pending CN1180318A (en) | 1996-02-23 | 1997-02-10 | Systems and methods for on-line finishing of cellular blood products like platelets harvested for therapeutic purposes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1180318A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100391134C (en) * | 2001-11-13 | 2008-05-28 | 松下电器产业株式会社 | Transmission method, transmission apparatus, and reception apparatus |
| CN106860480A (en) * | 2017-02-13 | 2017-06-20 | 武汉贝纳科技服务有限公司 | A kind of blood platelet and the preparation method containing hematoblastic preparation |
-
1997
- 1997-02-10 CN CN 97190084 patent/CN1180318A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100391134C (en) * | 2001-11-13 | 2008-05-28 | 松下电器产业株式会社 | Transmission method, transmission apparatus, and reception apparatus |
| CN106860480A (en) * | 2017-02-13 | 2017-06-20 | 武汉贝纳科技服务有限公司 | A kind of blood platelet and the preparation method containing hematoblastic preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6051147A (en) | Methods for on line finishing of cellular blood products like platelets harvested for therapeutic purposes | |
| US5298165A (en) | Method for removing leukocytes and a filter system for removing the same | |
| EP0829267B1 (en) | Pre-storage filtration of platelets | |
| DE69216767T2 (en) | DEVICE AND METHOD FOR REMOVING UNWANTED COMPONENTS FROM BLOOD CELLS | |
| DE69216995T2 (en) | DEVICES AND METHODS FOR REMOVING UNWANTED COMPONENTS FROM BLOOD CELLS | |
| US4330410A (en) | Separation of leukocytes from leukocyte-containing suspension by filtration | |
| EP0655012B1 (en) | Assembly and methods for processing blood | |
| US5236716A (en) | Platelets concentrate with low white blood cells content | |
| AU5982096A (en) | Apparatus and methods for mixing additive solutions | |
| WO1993017774A1 (en) | Filter and method for obtaining platelets | |
| NL9320033A (en) | System for handling transitional area material. | |
| JP2002526172A (en) | Biological fluid filters and systems | |
| CN1180318A (en) | Systems and methods for on-line finishing of cellular blood products like platelets harvested for therapeutic purposes | |
| JPS5854130B2 (en) | Leukocyte separation method | |
| JP4135894B2 (en) | Method, recovery device and recovery system for recovering blood from which leukocytes remaining on the leukocyte removal filter have been removed | |
| US20230173147A1 (en) | Blood separation system and blood products | |
| JPH0412986B2 (en) | ||
| JPS6353825B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |